KAER Biotherapeutics Corporation

3:30 PM - 3:45 PM (PDT), Monday, June 13, 2022
COVID-19 respiratory infections cause inflammation, marked reduction of pulmonary surfactant resulting in severe respiratory impairment, hypoxemia and 1M deaths in the US. An inhalation of 10-40 mg/kg of surfactant aerosols, effectively deposited into the peripheral lung, is predicted to improve gas exchange, reduce ventilation-induced intra-pulmonary stresses, inhibit viral/bacterial infections and save lives. KAER’s platform product lines, AersoPOD and SUPRAER-Utility, enable surfactant aerosols to be delivered as either liquid or solid-phase fine particle aerosols at high concentrations to patients ranging from infants to adults. Non-invasive aerosol treatment with proprietary pulmonary surfactant: 300,000 hypoxemia patients with 4 treatments at $5,000 each, represents $6B market opportunity. KAER is seeking $8M “A” round to accelerate manufacturing/ensure FDA compliance ($2.5M), conduct animal studies ($0.5M) and clinical studies ($3M), marketing/patents/G&A ($2M).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
AersoPOD and SUPRAER-Utility
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
AersoPOD and SUPRAER-Utility